A

Amgen

Makes biotech medicines for serious illnesses

Healthcare Community Contracting Sr Associate

Full-TimeUpdated on 10/22/2026
No salary listed
Senior
Bachelor's, Master's
Hyderabad, Telangana, India
In Person
Contract Management

About the job

Requirements
  • A Master's or Bachelor's degree and 5–8 years of related resource management, paralegal, contracting, and/or financial accounting experience are required.
  • Demonstrated ability to execute defined processes accurately, maintain documentation quality, and meet service-level expectations in a high-volume environment.
  • Excellent computer and Microsoft Office skills.
  • Excellent writing skills and attention to detail.
  • Ability to communicate effectively within and outside the department.
  • Familiarity with SAP.
  • Working knowledge of standard contracting and payment workflows, supplier onboarding, data-entry standards, and applicable enterprise systems.
  • Knowledge of current and legally binding contractual language and terminology.
  • Solid understanding of purchasing and supply chain procedures.
  • Solid understanding of standard operating procedures and healthcare regulations.
  • Solid understanding of standard contracting legal principles.
  • Ability to process simple transactions end to end, engaging business partners where appropriate.
  • Ability to identify and escalate business issues needing resolution, identify potential process improvements, and manage multiple assignments at one time.
  • Ability to identify missing information, validate submission completeness, and recognize discrepancies or out-of-process requests.
  • Ability to review and either approve payments or triage errors to the appropriate staff member.
  • Ability to review invoices and expenses related to Fee for Service Arrangements and triage issues.
  • Ability to review invoices and expenses related to Advisory Board Arrangements and triage issues.
  • Ability to communicate and escalate contractual and payment challenges to the leadership team.
  • Ability to exercise good judgment.
  • Ability to interact with business partners to ensure compliance processes and standards are understood and followed.
  • Ability to read legal documents and facilitate legal review, and interpret financial reports and technical documents.
  • Ability to manage payment inquiries received through the HCC Payment Requests mailbox, including further reviews, research, and triage.
  • Ability to communicate clearly and professionally with internal stakeholders and external participants to obtain information, confirm next steps, and support process completion.
  • Ability to proofread, edit, and fact-check legal documents for accuracy and consistency.
  • Time-management and problem-solving skills.
Responsibilities
  • Prepare, process, and coordinate standard agreements and amendments using approved templates and established contracting procedures; identify and escalate non-standard terms, exceptions, and complex matters for healthcare community engagements.
  • Maintain contract documentation and ensure compliance with contractual terms and conditions.
  • Coordinate end-to-end contract execution, including onboarding, maintenance actions, and distribution.
  • Maintain trackers, status fields, agreements, invoices, forms, expense documentation, and supporting materials in the approved system of record.
  • Triage intake from R&D or other supported functions to appropriate contract managers as needed.
  • Collaborate with sourcing, accounts payable, and other relevant teams to streamline financial processes and resolve issues or discrepancies.
  • Produce routine reports and data pulls on Fee for Service hours, contract status, aging, payment status, engagement history, and documentation completion.
  • Process invoices, reimbursements, and payments related to healthcare contracts.
  • Verify invoice accuracy and resolve discrepancies with suppliers and providers.
  • Ensure timely payments and adherence to payment terms.
  • Ensure compliance with internal controls, policies, and regulations.
  • Develop and enforce policies and procedures related to contracting and payment operations.
  • Participate in audits and assist with compliance-related activities as required.
  • Contribute to the development and implementation of strategic initiatives to optimize contracting and payment processes.
  • Review proposed arrangements through Amgen’s healthcare compliance operations system of record, C3.
  • Support Amgen staff with related questions and concerns, including C3 system support.
  • Perform other duties as assigned.
Desired Qualifications
  • Familiarity with the biopharmaceutical industry and medical and scientific terminology.
  • Knowledge of advocacy functionality at a large biotechnology organization.
  • Working understanding of healthcare regulations, contract terms, and payment processes.
  • Finance, resource, and budget management experience, including cost analysis and reporting.
  • Experience with analytics software such as Microsoft Access, Spotfire, Tableau, or Smartsheet; document management applications; portfolio planning tools; or supply chain and financial systems such as Planisware, Veeva, SAP, or Ariba.
  • Intermediate proficiency with Microsoft Office applications, including Excel, Word, PowerPoint, and Outlook.
  • Experience working with virtual teams and collaborative tools and platforms.
  • Ability to work in a highly cross-matrixed environment.
  • Strong planning and project-management skills, with demonstrated ability to work effectively in a fast-paced environment with multiple high-priority projects and minimal supervision.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.